Liraglutide (Victoza, Saxenda)

Mechanism of Action

Liraglutide is an acylated analog of human glucagon-like peptide-1 (GLP-1) with 97% structural homology to the native GLP-1(7-37) peptide. A single amino acid substitution (Arg34Lys) and the attachment of a C-16 palmitoyl fatty acid chain via a glutamic acid spacer at position 26 confer the pharmacokinetic properties that distinguish liraglutide from endogenous GLP-1.1 The fatty acid moiety enables non-covalent, reversible binding to serum albumin, which serves three functions: it shields the molecule from DPP-4 enzymatic degradation, reduces renal clearance, and creates a slow-release depot at the injection site. These modifications extend the plasma half-life from the ~2 minutes of native GLP-1 to approximately 13 hours, permitting once-daily subcutaneous administration.2

Upon binding the GLP-1 receptor on pancreatic beta cells, liraglutide activates the adenylyl cyclase–cAMP–PKA signaling cascade, potentiating glucose-dependent insulin secretion. This incretin effect is strictly glucose-dependent: insulin release is stimulated only when plasma glucose exceeds fasting thresholds, providing an intrinsic safeguard against hypoglycemia during monotherapy.13 Simultaneously, liraglutide suppresses inappropriately elevated glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, further contributing to improved glycemic control.2

Beyond the pancreas, liraglutide exerts clinically significant effects through multiple peripheral and central pathways. In the gastrointestinal tract, activation of GLP-1 receptors on vagal afferents and enteric neurons delays gastric emptying, which attenuates postprandial glucose excursions and contributes to early satiety.4 In the central nervous system, liraglutide activates GLP-1 receptors in the hypothalamic arcuate nucleus, paraventricular nucleus, and nucleus tractus solitarius, reducing appetite and food intake. The 3.0 mg dose used for weight management (Saxenda) produces a sustained reduction in caloric intake of approximately 16–20%, predominantly by reducing hunger and increasing satiety signaling.5

Evidence Summary

Glycemic Control (LEAD Program)

The Liraglutide Effect and Action in Diabetes (LEAD) clinical trial program evaluated liraglutide (1.2 mg and 1.8 mg daily) across six phase 3 RCTs in patients with type 2 diabetes. In LEAD-3, a 52-week monotherapy trial, liraglutide 1.8 mg demonstrated superior HbA1c reduction compared with glimepiride (-1.14% vs -0.51%; p<0.0001), with 51% of patients achieving HbA1c <7%.3 Across the LEAD program, liraglutide consistently demonstrated HbA1c reductions of 1.0–1.5% from baseline, with superiority over rosiglitazone (LEAD-1), glimepiride (LEAD-3), and noninferiority to insulin glargine (LEAD-5).23

Cardiovascular Outcomes (LEADER Trial)

The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial was a landmark double-blind, placebo-controlled cardiovascular outcomes trial enrolling 9,340 patients with type 2 diabetes and high cardiovascular risk. Over a median follow-up of 3.8 years, liraglutide 1.8 mg daily demonstrated a statistically significant 13% reduction in the primary composite endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) versus placebo (HR 0.87; 95% CI 0.78–0.97; p=0.01 for superiority).1 Cardiovascular death was reduced by 22% (HR 0.78; 95% CI 0.66–0.93; p=0.007), and all-cause mortality by 15% (HR 0.85; 95% CI 0.74–0.97; p=0.02).1

Weight Management (SCALE Program)

The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) program evaluated liraglutide 3.0 mg daily for chronic weight management. In the pivotal SCALE Obesity and Prediabetes trial, a 56-week double-blind RCT of 3,731 adults with BMI of 30 kg/m² or greater (or 27 kg/m² with comorbidity), liraglutide 3.0 mg achieved a mean body weight reduction of 8.0% versus 2.6% with placebo (treatment difference −5.4 percentage points; p<0.001).5 A total of 63.2% of liraglutide-treated participants achieved at least 5% weight loss (vs 27.1% with placebo), and 33.1% achieved at least 10% (vs 10.6%).5 In a 3-year extension, liraglutide reduced the incidence of type 2 diabetes by 79% compared with placebo in participants with prediabetes at baseline.6

Primary Uses

• Type 2 diabetes mellitus (Victoza, 1.2–1.8 mg/day subcutaneous): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. FDA-approved January 2010.28
• Chronic weight management (Saxenda, 3.0 mg/day subcutaneous): For adults with BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). Also approved for adolescents aged 12–17 years with body weight >60 kg and BMI corresponding to adult BMI of 30 kg/m² or greater. FDA-approved December 2014.58
• Cardiovascular risk reduction (Victoza, 1.8 mg/day subcutaneous): To reduce the risk of MACE in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial.1

Common Stacks & Synergies

Liraglutide is frequently used in combination with other therapies depending on the clinical indication. The following combinations are evidence-supported and commonly employed in clinical practice:

• Metformin + Liraglutide (T2D): The most common background therapy combination for type 2 diabetes. Metformin addresses hepatic glucose output and improves insulin sensitivity, while liraglutide enhances incretin-mediated insulin secretion and provides additional HbA1c reduction. In LEAD-2, liraglutide added to metformin produced additional HbA1c reductions of 1.0–1.5% versus metformin alone.23
• Basal insulin + Liraglutide (T2D): The combination of liraglutide and basal insulin (e.g., insulin degludec) is available as the fixed-ratio combination product Xultophy (insulin degludec/liraglutide). This approach provides complementary mechanisms: basal insulin addresses fasting glucose, while liraglutide targets postprandial glucose, appetite, and body weight.7
• Structured exercise + caloric restriction + Liraglutide (weight management): In the SCALE trials, all participants received lifestyle counseling including a 500 kcal/day deficit and 150 minutes/week of physical activity. The combination of pharmacotherapy and behavioral intervention yields more durable and greater weight loss than either alone.5

For detailed combination protocols and titration schedules, see our Protocols page.

Preparation & Administration

Subcutaneous Injection (Victoza / Saxenda)

Liraglutide is supplied as a clear, colorless solution in a pre-filled, multi-dose disposable pen (6 mg/mL for Victoza; 6 mg/mL for Saxenda). No reconstitution or dilution is required.

• Injection sites: Abdomen (at least 2 inches from navel), thigh (front or outer aspect), or upper arm (back of arm). Rotate injection sites with each dose to reduce the risk of lipodystrophy.
• Pen priming: For new pens, attach a new needle and prime by dialing to the flow check symbol, then press the injection button until a drop appears at the needle tip. Prime before each injection with a new needle.
• Injection technique: Clean the skin with an alcohol swab. Pinch the skin if needed, insert the needle at a 90-degree angle, press the dose button completely, and hold for at least 6 seconds before withdrawing to ensure full dose delivery.
• Timing: Inject once daily at any time of day, with or without meals. The injection time can vary from day to day but establishing a consistent routine is recommended.
• Pen needle compatibility: Use Novo Nordisk-approved pen needles (e.g., NovoFine or NovoTwist). Needles should never be shared between patients.

For detailed injection technique instruction and safety guidance, see our Injection Safety guide.

Side Effects & Adverse Events

Common Adverse Reactions (≥5%)

Gastrointestinal adverse events are the most frequently reported side effects and represent the primary reason for treatment discontinuation (~6–10% of patients). Most GI events are dose-dependent, mild to moderate in severity, and occur predominantly during dose escalation, tending to diminish with continued treatment.58

• Nausea: 15–40% (most common; dose-dependent, highest at 3.0 mg)
• Diarrhea: 10–17%
• Vomiting: 6–16%
• Constipation: 8–19%
• Dyspepsia / abdominal pain: 5–11%
• Headache: 11–14%
• Decreased appetite: 9–10%
• Fatigue: 5–8%
• Injection site reactions: 2–5% (erythema, pruritus, rash at injection site)

Serious Adverse Events

• Pancreatitis: Rare (reported in <0.5% of participants in clinical trials). Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported post-marketing. Discontinue immediately if pancreatitis is suspected.8
• Gallbladder events: Cholelithiasis and cholecystitis have been reported at higher rates than placebo in both the LEADER and SCALE programs, particularly at the 3.0 mg dose. In SCALE, gallbladder-related events occurred in 2.5% of liraglutide patients vs 1.0% in placebo.5
• Hypoglycemia: Low risk as monotherapy (<2%). Risk increases significantly when combined with insulin or sulfonylureas (up to 7–15%). Dose reduction of concomitant secretagogue or insulin is recommended.8
• Acute kidney injury: Reported primarily in the setting of severe dehydration from GI adverse events. Some cases have occurred in patients without known pre-existing renal disease. Monitor renal function in patients with renal impairment or GI complaints.8
• Thyroid C-cell tumors: Observed in rodent carcinogenicity studies at clinically relevant exposures. Relevance to humans is uncertain but cannot be excluded. Calcitonin monitoring is not recommended for routine screening. See Boxed Warning above.8
• Heart rate increase: Liraglutide increases resting heart rate by 2–3 bpm on average. In LEADER, this was not associated with adverse cardiovascular outcomes, but patients should be monitored.1

Drug Interactions

Liraglutide slows gastric emptying, which may affect the rate of absorption of concomitantly administered oral medications. While pharmacokinetic studies have not demonstrated clinically significant interactions for most tested compounds (acetaminophen, atorvastatin, griseofulvin, digoxin, lisinopril, oral contraceptives), the following interactions warrant clinical attention:8

• Oral medications with narrow therapeutic indices: Delayed gastric emptying may affect absorption kinetics. Exercise caution with drugs such as warfarin and levothyroxine. Monitor INR more frequently when initiating or titrating liraglutide in patients on warfarin.8
• Insulin and sulfonylureas: Concurrent use increases the risk of hypoglycemia. Consider reducing the dose of insulin or sulfonylurea when initiating liraglutide. In clinical trials, the sulfonylurea dose was reduced by 50% upon liraglutide initiation.38
• Other GLP-1 receptor agonists: Do not co-administer liraglutide with other GLP-1 receptor agonists. Victoza and Saxenda contain the same active ingredient and must never be used together.
• Oral contraceptives: A pharmacokinetic study showed liraglutide reduced the Cmax of ethinylestradiol and levonorgestrel by 12% and 13%, respectively, and delayed Tmax by 1.5 hours. Clinical significance is likely limited, but patients should be aware of the potential for delayed absorption.8

Storage & Handling

Pre-Filled Pens (Victoza / Saxenda)

• Before first use: Refrigerate at 36–46°F (2–8°C). Do not freeze. Do not use if the product has been frozen.
• After first use: Store at room temperature (59–86°F / 15–30°C) or refrigerated for up to 30 days. Discard the pen after 30 days regardless of remaining volume.
• Protect from light and heat: Keep the pen cap on when not in use. Do not store with a needle attached. Do not expose to excessive heat or direct sunlight.
• Do not use if the solution appears cloudy, discolored, or contains particles.

Legal & Regulatory Status

• United States (FDA): Approved. Victoza (subcutaneous, T2D) approved January 2010. Saxenda (subcutaneous, weight management) approved December 2014. Pediatric indication (Saxenda, ages 12–17) approved December 2020.8
• European Union (EMA): Approved. Victoza authorized June 2009. Saxenda authorized March 2015.
• Prescription status: Prescription only in all approved markets. Liraglutide is not a controlled substance.
• Manufacturer: Novo Nordisk A/S (Bagsværd, Denmark).
• Biosimilar / compounding status: No FDA-approved biosimilar as of April 2026. Compounded liraglutide is not FDA-approved and may carry additional risks. Liraglutide patents have faced biosimilar challenges in multiple jurisdictions.

Open Questions

Despite the extensive clinical evidence supporting liraglutide, several important questions remain under active investigation:

• Positioning versus newer GLP-1 receptor agonists: With the availability of once-weekly semaglutide and dual/triple agonists (tirzepatide, retatrutide), the relative role of daily liraglutide in clinical practice is evolving. Head-to-head data consistently show semaglutide achieves greater weight loss and HbA1c reduction, raising questions about liraglutide's continued first-line positioning.4
• Long-term weight maintenance: As with other anti-obesity medications, weight regain after liraglutide discontinuation is common. The SCALE Maintenance trial demonstrated continued benefit with ongoing therapy, but optimal treatment duration remains undefined.6
• Cardiovascular benefit in non-diabetic populations: LEADER enrolled only patients with type 2 diabetes. Whether liraglutide provides cardiovascular benefit in patients with obesity but without diabetes (as demonstrated for semaglutide in SELECT) remains untested.
• Cancer risk with long-term use: The rodent thyroid C-cell tumor signal has not been confirmed in humans after over 15 years of post-marketing surveillance, but ongoing pharmacovigilance continues. Long-term registry data are reassuring but not definitive.
• NASH/NAFLD application: Phase 2 data (LEAN trial) showed liraglutide resolved NASH in 39% of patients versus 9% with placebo. Whether liraglutide or newer GLP-1 agonists will achieve regulatory approval for NASH is an area of active clinical development.7